BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6900
- TODAY'S CHANGE (%)-0.0290 (-4.0334%)
- Bid / Lots0.6821/ 1
- Ask / Lots0.7170/ 20
- Open / Previous Close0.6870 / 0.7190
- Day Range
- 52 Week Range
- Volume229,863
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 9039 | 0.687 |
| 09:43 ET | 325 | 0.6608 |
| 09:45 ET | 100 | 0.6728 |
| 09:50 ET | 870 | 0.6728 |
| 09:56 ET | 100 | 0.6703 |
| 09:57 ET | 800 | 0.68401 |
| 09:59 ET | 550 | 0.680051 |
| 10:01 ET | 938 | 0.6926 |
| 10:03 ET | 1200 | 0.71 |
| 10:06 ET | 2000 | 0.675101 |
| 10:08 ET | 100 | 0.70591 |
| 10:10 ET | 600 | 0.7096 |
| 10:12 ET | 2602 | 0.68 |
| 10:15 ET | 1050 | 0.6801 |
| 10:28 ET | 1500 | 0.6801 |
| 10:33 ET | 100 | 0.6953 |
| 10:37 ET | 3045 | 0.69 |
| 10:42 ET | 1369 | 0.69 |
| 10:46 ET | 6543 | 0.69505 |
| 10:48 ET | 3613 | 0.7 |
| 10:50 ET | 450 | 0.705 |
| 10:53 ET | 100 | 0.7 |
| 10:57 ET | 2027 | 0.705 |
| 11:00 ET | 8814 | 0.701 |
| 11:02 ET | 1950 | 0.7084 |
| 11:04 ET | 1119 | 0.69 |
| 11:08 ET | 132 | 0.69 |
| 11:11 ET | 1000 | 0.690101 |
| 11:13 ET | 12400 | 0.675 |
| 11:24 ET | 100 | 0.685 |
| 11:27 ET | 200 | 0.685 |
| 11:31 ET | 2700 | 0.6968 |
| 11:33 ET | 1800 | 0.695 |
| 11:40 ET | 100 | 0.695 |
| 11:42 ET | 759 | 0.695 |
| 11:44 ET | 6700 | 0.695 |
| 11:45 ET | 6322 | 0.705 |
| 11:47 ET | 500 | 0.69 |
| 11:49 ET | 187 | 0.6825 |
| 11:56 ET | 6800 | 0.675 |
| 11:58 ET | 1000 | 0.6788 |
| 12:09 ET | 4600 | 0.6752 |
| 12:12 ET | 15859 | 0.663 |
| 12:14 ET | 11057 | 0.651 |
| 12:20 ET | 1384 | 0.660001 |
| 12:21 ET | 100 | 0.669999 |
| 12:25 ET | 1878 | 0.67 |
| 12:27 ET | 300 | 0.6675 |
| 12:34 ET | 4144 | 0.67 |
| 12:36 ET | 400 | 0.6775 |
| 12:43 ET | 540 | 0.67 |
| 12:50 ET | 1735 | 0.68 |
| 12:57 ET | 20225 | 0.705 |
| 12:59 ET | 1000 | 0.68 |
| 01:03 ET | 100 | 0.676 |
| 01:06 ET | 1867 | 0.67 |
| 01:10 ET | 1000 | 0.676001 |
| 01:12 ET | 1200 | 0.67 |
| 01:14 ET | 5210 | 0.67 |
| 01:28 ET | 450 | 0.671 |
| 01:33 ET | 800 | 0.682 |
| 01:37 ET | 1600 | 0.673 |
| 01:42 ET | 100 | 0.682 |
| 01:44 ET | 2900 | 0.682 |
| 01:51 ET | 1100 | 0.682 |
| 02:04 ET | 100 | 0.682 |
| 02:08 ET | 3700 | 0.682 |
| 02:09 ET | 500 | 0.682 |
| 02:18 ET | 100 | 0.7 |
| 02:20 ET | 100 | 0.695 |
| 02:26 ET | 100 | 0.69 |
| 02:33 ET | 4951 | 0.7042 |
| 02:36 ET | 200 | 0.7042 |
| 02:44 ET | 1000 | 0.6931 |
| 02:58 ET | 1636 | 0.7 |
| 03:02 ET | 300 | 0.6902 |
| 03:09 ET | 26499 | 0.7073 |
| 03:12 ET | 1000 | 0.7073 |
| 03:16 ET | 150 | 0.6874 |
| 03:18 ET | 910 | 0.7147 |
| 03:27 ET | 242 | 0.6997 |
| 03:30 ET | 100 | 0.6957 |
| 03:34 ET | 369 | 0.6876 |
| 03:36 ET | 1000 | 0.6876 |
| 03:41 ET | 1141 | 0.68218 |
| 03:48 ET | 300 | 0.6821 |
| 03:54 ET | 1300 | 0.6949 |
| 03:56 ET | 400 | 0.693 |
| 03:57 ET | 904 | 0.685 |
| 03:59 ET | 838 | 0.69 |
Today
Yesterday
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow JonesPress Release: BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow Jones
May 24, 2024
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, from 7:00AM ET on Friday May 24, 2024 by Dow Jones
7:00AM ET on Friday May 24, 2024 by Dow Jones
May 22, 2024
BioLineRx to Report First Quarter 2024 Results on May 28, 2024, from 7:00AM ET on Wednesday May 22, 2024 by Dow Jones
7:00AM ET on Wednesday May 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 57.9M | -0.7x | --- |
Dyadic International Inc | 57.3M | -7.9x | --- |
LAVA Therapeutics NV | 62.8M | -2.2x | --- |
Kezar Life Sciences Inc | 51.8M | -0.5x | --- |
Kronos Bio Inc | 45.4M | -0.4x | --- |
Evogene Ltd | 39.0M | -1.7x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $57.9M |
|---|---|
Revenue (TTM) | $4.8M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.53 |
EPS | $-0.95 |
Book Value | $0.18 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 12.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,035.29% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
